HUP9900666A2 - Új fenantridinszármazékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények - Google Patents

Új fenantridinszármazékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP9900666A2
HUP9900666A2 HU9900666A HUP9900666A HUP9900666A2 HU P9900666 A2 HUP9900666 A2 HU P9900666A2 HU 9900666 A HU9900666 A HU 9900666A HU P9900666 A HUP9900666 A HU P9900666A HU P9900666 A2 HUP9900666 A2 HU P9900666A2
Authority
HU
Hungary
Prior art keywords
hydrogen atom
pipe powder
alkyl
powder
pipe
Prior art date
Application number
HU9900666A
Other languages
English (en)
Inventor
Hermann Amschler
Rolf Beume
Hildegard Boss
Thomas Bär
Dieter Flockerzi
Karl-Josef Goebel
Beate Gutterer
Armin Hatzelmann
Dietrich Häfner
Hans-Peter Kley
Thomas Martin
Christian Schudt
Wolf-Rüdiger Ulrich
Original Assignee
Byk Gulden Lomberg Chemische Fabrik Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19603321A external-priority patent/DE19603321A1/de
Application filed by Byk Gulden Lomberg Chemische Fabrik Gmbh. filed Critical Byk Gulden Lomberg Chemische Fabrik Gmbh.
Publication of HUP9900666A2 publication Critical patent/HUP9900666A2/hu
Publication of HUP9900666A3 publication Critical patent/HUP9900666A3/hu
Publication of HU221380B1 publication Critical patent/HU221380B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

A cím szerinti vegyületek (I) általánős képletében R1 jelentésehidrőxil-, alkőxi-, ciklőalkőxi- vagy ciklőalkil-metőxi-csőpőrt vagyflűőrral teljesen vagy részlegesen helyetesített alkőxicsőpőrt, R2jelentése hidrőxil-, alkőxi-, ciklőalkőxi- vagy ciklő-alkil-etőxi-csőpőrt vagy flűőrral teljesen vagy részlegesen helyettesített alkőxi-csőpőrt, vagy R1 és R2 együtt 1-2 szénatőmős akilén-diőxi-csőpőrtőtképez, R3 jelentése hidrőgénatőm vagy alkőlcsőpőrt, R31 jelentésehidrőgénatőm vagy alkilcsőpőrt, vagy R3 és R11 együtt 1-4 szénatőmősalkiléncsőpőrtőt képez, R4 jelentése hidrőgénatőm vagy alkilcsőpőrt,R5 jelentése hidrőgénatőm, R51 jelentése hidrőgénatőm, vagy R5 és R51 együtt tővábbi kötét képez, R6 jelentése R7 általhelyettesített fenilcsőpőrt, ahől R7 jelentése -COOR71 vagy -CON(R72)R73 csőpőrt, ahől R71 jelentése hidrőgénatőm, alkil-,ciklőalkil- vagy ciklőalkil-metil-csőpőrt és R72 és R73 jelentéseegymástól függetlenül hidrőgénatőm, alkil-, ciklőalkil-, vagyciklőalkil-metil-csőpőrt és sóik értékes brőnchiális gyógyászatihatóanyagők. ŕ
HU9900666A 1996-01-31 1997-01-30 Phosphodiesterase inhibitor phenanthridines derivatives and use thereof HU221380B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19603321A DE19603321A1 (de) 1996-01-31 1996-01-31 Neue Phenanthridine
EP96101791 1996-02-08
PCT/EP1997/000402 WO1997028131A1 (de) 1996-01-31 1997-01-30 Neue phenanthridine

Publications (3)

Publication Number Publication Date
HUP9900666A2 true HUP9900666A2 (hu) 1999-06-28
HUP9900666A3 HUP9900666A3 (en) 2000-04-28
HU221380B1 HU221380B1 (en) 2002-09-28

Family

ID=26022482

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900666A HU221380B1 (en) 1996-01-31 1997-01-30 Phosphodiesterase inhibitor phenanthridines derivatives and use thereof

Country Status (19)

Country Link
US (1) US6191138B1 (hu)
EP (1) EP0882021B1 (hu)
JP (1) JP4138003B2 (hu)
KR (1) KR100454781B1 (hu)
AT (1) ATE233735T1 (hu)
BR (1) BR9707233A (hu)
CA (1) CA2245142C (hu)
CY (1) CY2473B1 (hu)
CZ (1) CZ289340B6 (hu)
DE (1) DE59709437D1 (hu)
DK (1) DK0882021T3 (hu)
EA (1) EA001205B1 (hu)
EE (1) EE03523B1 (hu)
ES (1) ES2194180T3 (hu)
HU (1) HU221380B1 (hu)
PT (1) PT882021E (hu)
SI (1) SI0882021T1 (hu)
UA (1) UA48216C2 (hu)
WO (1) WO1997028131A1 (hu)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0882021T1 (en) * 1996-01-31 2003-10-31 Altana Pharma Ag New phenanthridines
ES2217575T3 (es) * 1997-07-25 2004-11-01 Altana Pharma Ag Nuevos derivados de tetrazol.
IL133825A (en) * 1997-07-25 2005-12-18 Altana Pharma Ag Substituted 6-phenylphenanthridines, medicaments containing same and use thereof in the production of medicaments
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
CA2360386A1 (en) * 1999-01-15 2000-07-20 Beate Gutterer Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
PT1147087E (pt) 1999-01-15 2005-09-30 Altana Pharma Ag Feantridina-n-oxidos com actividade de inibicao de pde-iv
BR0007527B1 (pt) 1999-01-15 2011-12-27 fenilfenantridinas com atividade inibitària de pde-iv, seu uso, bem como medicamento compreendendo as mesmas.
ATE315029T1 (de) * 1999-01-15 2006-02-15 Altana Pharma Ag 6-arylphenanthridine mit pde-iv hemmender wirkung
US6534519B1 (en) 1999-01-15 2003-03-18 Altana Pharma Ag Phenanthridine-N-oxides with PDE-IV inhibiting activity
DE60043318D1 (de) 1999-08-21 2010-01-14 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
JP2003519686A (ja) 2000-01-11 2003-06-24 アルタナ ファルマ アクチエンゲゼルシャフト フェナントリジン−ｎ−オキシド
AU2001281965A1 (en) * 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Novel 6-phenylphenanthridines
WO2002006238A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
AU2001269126A1 (en) * 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Phenanthridine n-oxides
PT1303506E (pt) * 2000-07-14 2005-06-30 Altana Pharma Ag 6-heteroarilfenantridinas
ES2381862T3 (es) * 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
US20060116518A1 (en) * 2002-08-17 2006-06-01 Altana Pharma Ag Novel phenanthridines
ATE353217T1 (de) * 2002-08-29 2007-02-15 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
EP1539164B1 (en) 2002-08-29 2006-12-20 ALTANA Pharma AG 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
EP1658271A1 (en) * 2003-07-31 2006-05-24 ALTANA Pharma AG Novel 6-phenylphenanthridines
EP1658270A1 (en) * 2003-07-31 2006-05-24 ALTANA Pharma AG Novel 6-phenylphenantridines
MXPA06002521A (es) * 2003-09-05 2006-06-20 Altana Pharma Ag Uso de inhibidores de pde4 para el tratamiento de diabetes mellitus.
US7585872B2 (en) 2004-02-18 2009-09-08 Nycomed Gmbh Guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (PDE) 4 inhibitors
CN104803973A (zh) 2004-03-03 2015-07-29 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
AU2005220034A1 (en) * 2004-03-09 2005-09-15 Nycomed Gmbh Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
WO2005085203A1 (en) * 2004-03-10 2005-09-15 Altana Pharma Ag Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
WO2005087744A1 (en) * 2004-03-10 2005-09-22 Altana Pharma Ag Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
NZ549254A (en) * 2004-03-10 2010-06-25 Nycomed Gmbh Amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
ATE508130T1 (de) * 2004-09-08 2011-05-15 Nycomed Gmbh 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren
US7589205B2 (en) * 2004-09-08 2009-09-15 Nycomed Gmbh 3-thia-10-aza-phenanthrene derivatives
US7411093B2 (en) * 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu
BRPI0609371A2 (pt) 2005-03-08 2010-03-30 Nycomed Gmbh usos de roflumilast na produção de composições farmacêuticas para o tratamento de diabetes mellitus
AU2006221957A1 (en) * 2005-03-09 2006-09-14 Nycomed Gmbh Amido-substituted 6-phenylphenanthridines
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
RU2470011C2 (ru) * 2007-05-31 2012-12-20 Сепракор Инк. Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101067069B1 (ko) * 2009-03-09 2011-09-22 부경대학교 산학협력단 트리플루오로아세트산을 이용한 페난트리딘 유도체의 제조방법
CN102179655B (zh) * 2011-06-01 2013-09-04 柳州市久日工程机械有限公司 履带梁拼搭气动工装
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP7234470B2 (ja) 2015-10-30 2023-03-08 トーヨーカネツ株式会社 立体自動倉庫

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE786031A (fr) * 1971-07-08 1973-01-08 Rhone Poulenc Sa Nouveaux derives de la phenanthridine, leur preparation et les compositions medicinales qui les contiennent
US4309545A (en) * 1980-07-28 1982-01-05 Pfizer Inc. Oximino-1-hydroxyoctahydrobenzo[c]quinolines and derivatives thereof
SI0882021T1 (en) * 1996-01-31 2003-10-31 Altana Pharma Ag New phenanthridines

Also Published As

Publication number Publication date
CZ241498A3 (cs) 1998-12-16
DK0882021T3 (da) 2003-06-23
HU221380B1 (en) 2002-09-28
JP2000503996A (ja) 2000-04-04
EA001205B1 (ru) 2000-12-25
PT882021E (pt) 2003-07-31
HUP9900666A3 (en) 2000-04-28
CZ289340B6 (cs) 2002-01-16
EP0882021B1 (de) 2003-03-05
CA2245142A1 (en) 1997-08-07
CY2473B1 (en) 2005-06-03
SI0882021T1 (en) 2003-10-31
KR19990082143A (ko) 1999-11-15
UA48216C2 (uk) 2002-08-15
CA2245142C (en) 2004-11-30
KR100454781B1 (ko) 2005-04-08
DE59709437D1 (de) 2003-04-10
JP4138003B2 (ja) 2008-08-20
ATE233735T1 (de) 2003-03-15
EE03523B1 (et) 2001-10-15
US6191138B1 (en) 2001-02-20
EE9800223A (et) 1998-12-15
EP0882021A1 (de) 1998-12-09
WO1997028131A1 (de) 1997-08-07
BR9707233A (pt) 1999-07-20
EA199800667A1 (ru) 1999-02-25
ES2194180T3 (es) 2003-11-16

Similar Documents

Publication Publication Date Title
HUP9900666A2 (hu) Új fenantridinszármazékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
HUP9802822A2 (hu) Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
HUP9802304A2 (hu) Piridazin-3-on-származékok, intermedierjeik, alkalmazásuk, a vegyületeket hatóanyagként tartalmazó herbicid készítmények
CO5050332A1 (es) Composiciones fungicidas que comprenden 2-metoxibenzofenonas
MX9203165A (es) Derivados de succinimida y composicion farmaceutica que los contiene .
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
CY1110904T1 (el) Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun
HUP9700159A2 (hu) Benzil-szulfid-származékok, intermedierjeik, eljárás előállításukra és a vegyületeket hatóanyagként tartalmazó inszekticid készítmények
ES2143487T3 (es) 1,2,4-oxadiazolil-fenoxialquilisoxazoles y su empleo como agentes antivirales.
TR200000918T2 (tr) Halojen ikameli tetrasiklik tetrahidrofuran türevleri.
SE0201937D0 (sv) Therapeutic agents
FI860111A (fi) Terapeutiska medel.
IL110979A (en) Substituted 17beta-anilide-4-aza-5alpha-androstan-3-ones their preparation and pharmaceutical compositions containing them
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
ATE49211T1 (de) Dreizyklische oxindole als antientzuendungsmittel.
IL110831A0 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
NZ227400A (en) Thiol-ketone and thiol-aldehyde derivatives, intermediates thereof and pharmaceutical compositions
IE832109L (en) 1-arylcyclobutylalkylamine compounds
EP0335979A4 (en) Thienopyrimidine derivatives
ATE52249T1 (de) Aminoalkyl-substituierte harnstoffderivate, deren saeureadditionssalze und enantiomere.
AR006480A1 (es) Derivados diamidicos del acido piridin-2,3-dicarboxilico y herbicidas que comprenden dichos derivados como ingrediente activo
HUP9801229A2 (hu) Eljárás 5,6-dihidro-1,3-oxazin-származékok előállítására, intermedierjeik, hatóanyagként ezeket a vegyületeket tartalmazó inszekticid, arachnicid és nematocid készítmények és alkalmazásuk
MY103521A (en) Bicyclocatechol derivatives
BG102429A (en) Derivatives of 5-naphthalen-1-yl-1,3-dioxan, their preparation and usage as therapeutical means

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ALTANA PHARMA AG, DE

Free format text: FORMER OWNER(S): BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH., DE

MM4A Lapse of definitive patent protection due to non-payment of fees